| Document |
Document Title |
|
WO/2012/060396A1 |
The purpose of the present invention is to provide a novel trans-2-decenoic acid derivative and a pharmaceutically acceptable salt thereof, and a medicament containing the compound described above as an active component and having a neur...
|
|
WO/2012/055014A1 |
Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R=C(0); -OC(O)- or -CH( OH)-; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A snd B ...
|
|
WO/2012/050593A1 |
Disclosed is a method of making a 2-substituted-1,4-benzenediamine by nucleophilic aromatic substitution.
|
|
WO/2012/050263A1 |
Provided is a method of preparing endoxifen by coupling 4,4-hydroxybenzophenone as a starting material with propiophenone. The method can be used to obtain an E/Z-form endoxifen mixture with a high yield compared to the conventional meth...
|
|
WO/2012/050623A2 |
The present invention provides a process for the synthesis of substituted phenoxymethylpropionic acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).
|
|
WO/2012/045883A1 |
The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer.
|
|
WO/2012/040853A1 |
The present invention provides Group 5 metal complexes useful for amine functionalization and synthetic process for manufacture thereof. Provided in this application are halo group 5 metal-amidate complexes having the structure of Formul...
|
|
WO/2012/044758A1 |
Disclosed is a method of making 2-methoxymethyl-1,4-benzenediamine that includes hydrogenating 1-benzylamino-2-(methoxymethyl)-4-nitrobenzene in the presence of a hydrogenation catalyst.
|
|
WO/2012/040133A2 |
Novel radiotracer(s) for Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging of disease states related to altered choline metabolism (e.g., tumor imaging of prostate, breast, brain, esophageal...
|
|
WO/2012/040151A2 |
Novel radiotracer(s) for Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging of disease states related to altered choline metabolism (e.g., tumor imaging of prostate, breast, brain, esophageal...
|
|
WO/2012/040138A2 |
Novel radiotracer(s) for Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging of disease states related to altered choline metabolism (e.g., tumor imaging of prostate, breast, brain, esophageal...
|
|
WO/2012/038974A1 |
Provided is a process for the preparing l-phenyl-3-dimethylaminopropane derivatives of formula I, (The formula should be inserted here) and its pharmaceutically acceptable salts thereof via novel intermediates.
|
|
WO/2012/029794A1 |
The present invention provides an aromatic compound containing a specific branch. This aromatic compound containing a specific branch is easily soluble in isopropyl acetate, which is excellent for separating liquids, and can be used for ...
|
|
WO/2012/028323A1 |
Described is a process for the preparation of halogenated 4,4'-methylene-bis- anilines by a direct halogenation of 4,4'-methylene-bis-anilines. High yields and a flexible control of the grade of halogenation at the aromatic rings can be ...
|
|
WO/2012/023546A1 |
The purpose of the present invention is to provide a process by which hydrogen or heavy hydrogens can be easily produced without using large-scale equipment and a process by which hydrogenation (protiation, deuteration or tritiation) can...
|
|
WO/2012/020418A1 |
The present invention relates to novel polymorphs of 4-hydroxy Atomoxetine hydrochloride and process for the preparation thereof. The present invention also relates to crystalline monohydrate and anhydrate forms of 4-hydroxy Atomoxetine ...
|
|
WO/2012/020742A1 |
Disclosed is a novel compound that acts as an antagonist for P2X3 and/or P2X2/3 receptors. Also disclosed is a pharmaceutical composition that acts as an antagonist for P2X3 and/or P2X2/3 receptors, said composition containing: a compoun...
|
|
WO/2012/013691A1 |
Biphenyl diol compounds of formula (I) and their use as a medicament to suppress tumor growth and/or prevent recurrence or metastasis or to treat a cancer selected from the group consisting of brain, bone, colon, ovary, pancreas, prostat...
|
|
WO/2012/009472A2 |
The present disclosure provides novel oligo phenylene ethynylene (OPE) compounds, methods for synthesizing these compounds, and materials and substances incorporating these compounds. The various OPEs show antibacterial, antiviral and an...
|
|
WO/2012/005693A1 |
The present invention relates to a method for the synthesis of an α amino acetal, comprising (i) oxidizing a tertiary amine in the presence of a copper catalyst, at least one oxidant and a solvent, or (ii) reacting a secondary amine and...
|
|
WO/2012/002465A1 |
Disclosed are: a material for a liquid crystal alignment film, which does not undergo film detachment or scratching during rubbing even when the material is burned at a temperature of 200˚C or lower and can achieve good liquid crystal a...
|
|
WO/2012/001571A1 |
The object of the present invention is a new process for the synthesis of tapentadol, both as free base and in hydrochloride form, which comprises the step of alkylation of the ketone (VII) to yield the compound (VIII), as reported in Di...
|
|
WO/2012/000498A1 |
The present invention relates to the crystalline, polymorphic Form C of the calcimimetic compound {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl
]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of chara...
|
|
WO/2012/000499A1 |
The present invention relates to the crystalline, polymorphic Form X of the calcimimetic compound {4-[(1R, 3S)-3-((R)-1 -Naphthalen-1 -yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of cha...
|
|
WO/2011/157390A2 |
The present invention relates to a process for the preparation of substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds.
|
|
WO/2011/158959A1 |
Disclosed is a process for producing an intermediate for a cyclic carbodiimide compound. Specifically disclosed are: a process for producing an amine compound represented by formula (B), which involves a step of reducing a nitro compound...
|
|
WO/2011/154140A2 |
A novel process for the preparation of N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, also known as agomelatine, Compound (I), from 7-methoxy-tetralone as starting material, and to a new crystalline form X of agomelatine.
|
|
WO/2011/147576A1 |
The present invention relates to a process for the preparation of substituted 1-aminomethyl-2-phenyl-cyclohexane compounds.
|
|
WO/2011/145019A1 |
The present invention relates to an improved process for the preparation of biologically active diphenylpropylamine derivatives. The present invention specifically relates to an improved fesoterodine of formula (I) and its pharmaceutical...
|
|
WO/2011/144651A1 |
The invention relates to a method for producing 2-(2-tert.-butylamino-ethoxy)-ethanol (tert.-butylaminodiglycol, TBADG) by reacting diethylene glycol (DG) with tert.-butylamine (TBA) in the presence of hydrogen and a copper-containing ca...
|
|
WO/2011/141705A1 |
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic ...
|
|
WO/2011/141704A1 |
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid- lipid particles that provide efficient encapsulation of nucleic...
|
|
WO/2011/136368A1 |
Disclosed is a cationic lipid which is represented by formula (I) and makes it easier to introduce a nucleic acid into a cell. (In formula (I), R1 and R2 may be the same or different and each represents an alkenyl group or the like; X1 a...
|
|
WO/2011/136369A1 |
Disclosed is a cationic lipid which is represented by formula (I) and makes it easier to introduce a nucleic acid into a cell. (In formula (I), R1 and R2 may be the same or different and each represents a (Z)-pentadekenyl group, a (Z)-he...
|
|
WO/2011/131697A1 |
The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (Α'), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, h...
|
|
WO/2011/130194A2 |
Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantiall...
|
|
WO/2011/107705A1 |
The present invention relates to ketobenzofuran derivatives of the general formula (D) shown below, as well as to a method for synthesising same by coupling a quinonimine and an enaminone by a Nenitzescu reaction and to the intermediates...
|
|
WO/2011/105576A1 |
Disclosed are: a liquid crystal aligning agent which is capable of providing a liquid crystal alignment film that has high rubbing resistance, good liquid crystal aligning properties and high voltage holding ratio; a polymer for the liqu...
|
|
WO/2011/105088A1 |
Disclosed is a novel diamine compound, shown in equation (1). In equation (1), A represents an aromatic group (number of rings 4 or less) or a divalent aliphatic group (carbon number 10 or less) with an optional substituent. The disclose...
|
|
WO/2011/097336A2 |
Highly selective 5-HT(2C) receptor agonists receptors are disclosed. The 5-HT(2C) receptor agonists are used in the treatments of disease and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psy...
|
|
WO/2011/086115A2 |
The invention relates to a compound comprising a pesticide and an alkoxylate. The invention further relates to the alkoxylate, to a method for the production thereof, and to the use thereof as an auxiliary agent in pesticide-containing s...
|
|
WO/2011/085454A1 |
The present invention provides for novel benzene compounds and saccharide compounds and for the use of said compounds for binding, titration (quantification), removing, purifying or separating the glycoprotein gp120, gp120 comprising vir...
|
|
WO/2011/084810A2 |
New triaminophenol compositions and related compounds are disclosed, as are processes for their preparation and for the preparation of novel salts and diacid complexes from such compounds. Polymers prepared from these compositions can be...
|
|
WO/2011/079439A1 |
The present invention relates to a kind of novel carbene ligands and corresponding new ruthenium catalysts, which are highly active and selective for ROMP and RCM reactions. It discloses the significant electronic effect of different sub...
|
|
WO/2011/078295A1 |
Provided is a protecting reagent which can undergo deprotection in high yield even under acidic conditions in organic syntheses, e.g., peptide synthesis, and which enables high-purity products to be obtained. The protecting reagent is a ...
|
|
WO/2011/076708A1 |
The present application relates to compounds of formula (I): and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compound...
|
|
WO/2011/068209A1 |
Disclosed are: a composition containing an intermediate for a water-soluble monomer, which can be used suitably for the production of a water-soluble poly(alkylene glycol) monomer that has a polymerizable double bond at the terminal, can...
|
|
WO/2011/068987A2 |
Methods of treating exposure to Giardia lamblia and/or giardiasis and methods of antagonizing Giardia lamblia attachment to the intestinal wall of a subject are described herein.
|
|
WO/2011/065420A1 |
Provided is a novel method for manufacturing a 6-substituted-1-methyl-1H-benzimidazole derivative. Also provided is a manufacturing intermediate from said method. The provided method, which manufactures a 6-substituted-1-methyl-1H-benzim...
|
|
WO/2011/065530A1 |
Disclosed is an organic luminous element, in which an organic layer can be formed by coating and which has a long service life. Specifically disclosed is an organic luminous element which comprises a pair of electrodes and an organic com...
|
